A5040463428- Brain Metastases and Treatment
- Nanoplatforms for cancer theranostics
- Multiple Sclerosis Research Studies
- Radiopharmaceutical Chemistry and Applications
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Glioma Diagnosis and Treatment
- Neuroscience and Neuropharmacology Research
- Lanthanide and Transition Metal Complexes
- Advanced MRI Techniques and Applications
- Pharmacological Effects and Toxicity Studies
- Neuroendocrine regulation and behavior
- RNA Interference and Gene Delivery
- Nanoparticle-Based Drug Delivery
- Lung Cancer Research Studies
- Anesthesia and Sedative Agents
- Immunotherapy and Immune Responses
- Herpesvirus Infections and Treatments
- Anesthesia and Neurotoxicity Research
- Receptor Mechanisms and Signaling
BBB Therapeutics (Netherlands)
2012-2015
In a prospective multi-center observational study, we evaluated the frequency, severity, and impact on activities of daily living (ADL) adverse effects (AEs) high-dose intravenous methylprednisolone (IVMP) in relapsing remitting multiple sclerosis (MS) patients with relapse. Online self-report questionnaires stating IVMP's most common AEs were completed at baseline, 2nd day treatment, 1 week after treatment. Eighty-five included, 66 baseline questionnaire, 59 least one post-baseline...
Abstract Without active delivery across the blood-brain barrier (BBB) efficacy of doxorubicin in brain tumors is limited. 2B3-101, glutathione PEGylated liposomal doxorubicin, has been developed as brain-targeted chemotherapy. In preclinical studies, 2B3-101 showed a 5-fold enhanced brain-delivery versus pegylated (Doxil®). Patients with either solid tumor metastases or recurrent malignant gliomas were treated by 90 min IV infusion q21d to assess (1) safety, tolerability and MTD (2)...
Aims Intravenous high‐dose free methylprednisolone (MP) hemisuccinate is the primary treatment for an acute relapse in relapsing–remitting multiple sclerosis. However, it inconvenient and its side effects are undesirable. Both dose dosing frequency can be reduced by incorporating MP glutathione‐PEGylated liposomes, creating a slow‐release formulation with toxicity prolonged peripheral efficacy. This first‐in‐human study was designed to assess safety, pharmacokinetics pharmacodynamics of...
Abstract Treatment options for brain cancer are limited and overall prognoses poor. Glutathione pegylated liposomal doxorubicin (2B3-101) is being developed as a new treatment option patients with cancer. It essentially based on the already marketed (Doxil), an additional glutathione (GSH) coating to safely enhance delivery across blood-brain barrier. In GLP safety study 2B3-101 was administered by intravenous bolus injection days 1, 15 29 Wistar rats at 1.75, 3.5 7 mg/kg. Doxil (7 mg/kg),...
The objective of the present investigation was to characterize in vivo EEG effects (synthetic) neuroactive steroids on basis a recently proposed mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model. After intravenous administration, time course effect pregnanolone, 2β-3α-5α-3-hydroxy-2-(2,2-dimethylmorpholin-4-yl)-pregnan-11,20-dione (ORG 21465), 2β-3α-5α-21-chloro-3-hydroxy-2-(4-morpholinyl)-pregnan-20-one 20599), and alphaxalone determined conjunction with plasma concentrations...
Abstract Background: The incidence of brain metastases (BM) in breast cancer (BC) patients (pts) has increased over the past decade. is regarded as a sanctuary site for metastatic cells which are partially protected from drugs by blood-brain barrier (BBB). 2B3-101 doxorubicin (DOX) liposomal formulation that uses glutathione transporters on BBB to penetrate brain. Non-clinical studies have shown 5-fold enhanced delivery DOX after IV administration compared DOX, without signs cardio- or...